Evidence map›Paper›PMID 40321182›Full record

ArticleChemical science2025

TRAP: a contrastive learning-enhanced framework for robust TCR-pMHC binding prediction with improved generalizability.

Jingxuan Ge, Jike Wang, Qing Ye, Liqiang Pan, Yu Kang, Chao Shen, Yafeng Deng, Chang-Yu Hsieh, Tingjun Hou

Abstract read
In one paragraph

Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingxuan GeCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.ORCID https://orcid.org/0009-0006-9835-5660
Jike WangCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.
Qing YeCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.
Liqiang PanCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.
Yu KangCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.ORCID https://orcid.org/0000-0002-0999-8802
Chao ShenCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.ORCID https://orcid.org/0000-0003-2783-5529
Yafeng DengCarbonSilicon AI Technology Company, Ltd Hangzhou 310018 Zhejiang China.
Chang-Yu HsiehCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.ORCID https://orcid.org/0000-0002-6242-4218
Tingjun HouCollege of Pharmaceutical Sciences, Zhejiang University Hangzhou 310058 Zhejiang China kimhsieh@zju.edu.cn tingjunhou@zju.edu.cn.ORCID https://orcid.org/0000-0001-7227-2580

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The binding of T cell receptors (TCRs) to peptide-MHC I (pMHC) complexes is critical for triggering adaptive immune responses to potential health threats. Developing highly accurate machine learning (ML) models to predict TCR-pMHC binding could significantly accelerate immunotherapy advancements. However, existing ML models for TCR-pMHC binding prediction often underperform with unseen epitopes, severely limiting their applicability. We introduce TRAP, which leverages contrastive learning to enhance model performance by aligning structural and sequence features of pMHC with TCR sequences. TRAP outperforms previous state-of-the-art models in both random and unseen epitope scenarios, achieving an AUPR of 0.84 (a 22% improvement over the second-best model) and an AUC of 0.92 in the random scenario, and an AUC of 0.75 (almost 11% higher than the second-best model) in the unseen epitope scenario. Furthermore, TRAP demonstrates a noteworthy capability to diagnose potential issues of cross-reactivity between TCRs and similar epitopes. This highly robust performance makes it a suitable tool for large-scale predictions in real-world settings. A specific case study confirmed that TRAP can discover hit TCRs with binding free energies comparable to referenced experimental results. These findings highlight TRAP's potential for practical applications and its role as a powerful tool in developing TCR-based immunotherapies.

Identifiers

PMID40321182
PMCPMC12046420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.